Organon & Co. (NYSE:OGN) Issues Earnings Results

Organon & Co. (NYSE:OGN) released its quarterly earnings data on Monday. The company reported $0.93 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.93, Zacks reports. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. Organon & Co. updated its FY 2025 guidance to EPS.

Organon & Co. Stock Performance

OGN opened at $7.06 on Monday. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 11.98. Organon & Co. has a 52-week low of $6.18 and a 52-week high of $17.23. The company has a market cap of $1.83 billion, a P/E ratio of 2.62, a price-to-earnings-growth ratio of 0.61 and a beta of 0.59. The firm’s 50-day moving average price is $9.40 and its 200-day moving average price is $9.55.

Institutional Trading of Organon & Co.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new position in Organon & Co. in the second quarter valued at approximately $107,000. Gamco Investors INC. ET AL purchased a new position in Organon & Co. in the second quarter valued at $119,000. Cresset Asset Management LLC purchased a new stake in shares of Organon & Co. during the 2nd quarter worth about $134,000. Humankind Investments LLC grew its position in shares of Organon & Co. by 50.8% during the 2nd quarter. Humankind Investments LLC now owns 17,060 shares of the company’s stock valued at $165,000 after acquiring an additional 5,748 shares during the period. Finally, Canada Pension Plan Investment Board increased its stake in shares of Organon & Co. by 33.1% in the 2nd quarter. Canada Pension Plan Investment Board now owns 21,700 shares of the company’s stock valued at $210,000 after purchasing an additional 5,400 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on OGN shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of Organon & Co. in a research report on Wednesday, October 8th. Piper Sandler cut Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price objective on the stock. in a report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Organon & Co. has a consensus rating of “Hold” and an average target price of $13.00.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.